• Successful launch of Remplir at Hong Kong Orthopaedic Association 45th Annual Congress
• Remplir now selling in Australia, New Zealand, Singapore, the US and Hong Kong, with Canada and Thailand to follow
• Hong Kong serves as a strategic entry point into the Guangdong-Hong Kong-Macao Greater Bay Area

Orthocell Limited (ASX: OCC) has announced the successful completion of the first Remplir™ surgical case in Hong Kong and the launch of their flagship nerve repair medical device at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress. These achievements mark important milestones in Orthocell's Asia-Pacific commercialisation program and closely follow the appointment of MontsMed as the exclusive in-country distributor for Remplir in Hong Kong. With regulatory approval secured and a strong local distribution partner in place, Orthocell is now positioned to drive market penetration through leading hospitals and specialist surgeons. Hong Kong has strategic importance in the overall commercialisation program, serving as a gateway to the Guangdong-Hong Kong-Macao Greater Bay Area (GBA)--a region encompassing nine major cities and a population of approximately 100 million people. Under the Regulatory Innovation and Development of Pharmaceutical and Medical Device work plan, Hong Kong-registered medical devices such as Remplir may be imported by designated GBA healthcare institutions to meet urgent clinical needs. The launch at the HKOA 45th Annual Congress provided an excellent opportunity to introduce Remplir to key opinion leaders and specialists in orthopaedic and reconstructive surgery, and to highlight Remplir's clinical advantages in nerve repair and the growing body of evidence supporting improved patient outcomes. Orthocell's global commercialisation program continues to build momentum, with initial surgeries using Remplir completed in Singapore, the USA, and now Hong Kong in the past 12 months. Sales in Canada (a US$75 million market) and Thailand are expected to commence in the near term, supported by local distributor partnerships. The Company's Asian distributor network and regional commercial strategy will be overseen by Commercial Director Mr Hamish Thrum, who brings extensive experience across the ANZ and APAC medical device sectors. With over A$50 million in cash and no debt, Orthocell remains strongly funded and well-positioned to drive rapid product adoption and deliver a step change in revenue in FY26.

Orthocell expects sales in Canada (a US$75 million market) and Thailand to commence in the near term, supported by local distributor partnerships.

Orthocell remains strongly funded with over A$50 million in cash and no debt, and is well-positioned to drive rapid product adoption and deliver a step change in revenue in FY26.